Overview

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Dofetilide